Citigroup’s Corbus Pharmaceuticals CRBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $106K | Sell |
11,319
-5,389
| -32% | -$51K | ﹤0.01% | 4653 |
|
|
2026
Q1 | $157K | Buy |
16,708
+11,454
| +218% | +$96.4K | ﹤0.01% | 4094 |
|
|
2025
Q4 | $42.8K | Buy |
+5,254
| New | +$64.8K | ﹤0.01% | 4628 |
|
|
2025
Q3 | – | Sell |
-1,657
| Closed | -$11.4K | – | 6123 |
|
|
2025
Q2 | $11.4K | Sell |
1,657
-6,641
| -80% | -$48.2K | ﹤0.01% | 5166 |
|
|
2025
Q1 | $44.1K | Sell |
8,298
-912
| -10% | -$8.05K | ﹤0.01% | 4908 |
|
|
2024
Q4 | $109K | Buy |
9,210
+1,726
| +23% | +$28.9K | ﹤0.01% | 4796 |
|
|
2024
Q3 | $154K | Buy |
7,484
+3,101
| +71% | +$159K | ﹤0.01% | 4530 |
|
|
2024
Q2 | $198K | Sell |
4,383
-10,924
| -71% | -$459K | ﹤0.01% | 3876 |
|
|
2024
Q1 | $601K | Buy |
15,307
+14,741
| +2,604% | +$363K | ﹤0.01% | 3442 |
|
|
2023
Q4 | $3.42K | Buy |
+566
| New | +$3.04K | ﹤0.01% | 5371 |
|
|
2021
Q4 | – | Sell |
-3
| Closed | – | – | 5856 |
|
|
2021
Q3 | $0 | Sell |
3
-384
| -99% | -$15.1K | ﹤0.01% | 5829 |
|
|
2021
Q2 | $21K | Sell |
387
-169
| -30% | -$9.38K | ﹤0.01% | 5265 |
|
|
2021
Q1 | $33K | Sell |
556
-505
| -48% | -$33.2K | ﹤0.01% | 4944 |
|
|
2020
Q4 | $40K | Sell |
1,061
-1,124
| -51% | -$42K | ﹤0.01% | 6194 |
|
|
2020
Q3 | $118K | Sell |
2,185
-536
| -20% | -$97.1K | ﹤0.01% | 4985 |
|
|
2020
Q2 | $685K | Buy |
2,721
+524
| +24% | +$106K | ﹤0.01% | 3933 |
|
|
2020
Q1 | $345K | Sell |
2,197
-953
| -30% | -$161K | ﹤0.01% | 4218 |
|
|
2019
Q4 | $516K | Buy |
3,150
+1,723
| +121% | +$255K | ﹤0.01% | 4396 |
|
|
2019
Q3 | $208K | Sell |
1,427
-104
| -7% | -$18.1K | ﹤0.01% | 5121 |
|
|
2019
Q2 | $318K | Sell |
1,531
-443
| -22% | -$94.8K | ﹤0.01% | 4869 |
|
|
2019
Q1 | $411K | Buy |
1,974
+103
| +6% | +$22.7K | ﹤0.01% | 4388 |
|
|
2018
Q4 | $329K | Sell |
1,871
-199
| -10% | -$39.7K | ﹤0.01% | 4542 |
|
|
2018
Q3 | $469K | Buy |
2,070
+594
| +40% | +$96K | ﹤0.01% | 4362 |
|
|
2018
Q2 | $224K | Buy |
1,476
+343
| +30% | +$62.3K | ﹤0.01% | 4944 |
|
|
2018
Q1 | $207K | Buy |
1,133
+392
| +53% | +$88K | ﹤0.01% | 4933 |
|
|
2017
Q4 | $158K | Buy |
741
+656
| +772% | +$140K | ﹤0.01% | 5259 |
|
|
2017
Q3 | $18K | Buy |
85
+75
| +750% | +$14.7K | ﹤0.01% | 6470 |
|
|
2017
Q2 | $2K | Sell |
10
-43
| -81% | -$8.43K | ﹤0.01% | 6970 |
|
|
2017
Q1 | $13K | Buy |
+53
| New | +$13K | ﹤0.01% | 6457 |
|
Other funds holding CRBP
CAM
O
JHC
PM
SCM
ACM
Citigroup's CRBP Position: Q2 2026 in Review
Citigroup reduced its Corbus Pharmaceuticals (CRBP) stake by 32% in Q2 2026, selling an estimated $51K and leaving 11,319 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #4653.
Citigroup first reported a position in CRBP in Q1 2017 and has held it in 29 quarters since. The position peaked at $685K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.
- Citigroup held 11,319 shares of Corbus Pharmaceuticals worth $106K as of Q2 2026.
- Citigroup sold 5,389 Corbus Pharmaceuticals shares in Q2 2026, an estimated $51K.
- Corbus Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4653 holding.
- Citigroup first reported a position in Corbus Pharmaceuticals in Q1 2017 and has held it in 29 quarters since.
- Citigroup's Corbus Pharmaceuticals position peaked at $685K in Q2 2020.
- 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.